Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

33.7K
Overview
33.7K
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

1.8K
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
1.8K
Hybridoma Technology01:31

Hybridoma Technology

18.3K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and immunogenicity testing of a melioidosis subunit vaccine candidate in cynomolgus macaques.

NPJ vaccines·2026
Same author

Experimental model systems to study vascular aging.

Ageing research reviews·2026
Same author

Changing Patterns of Hospitalisation and Orthopaedic Procedure Profiles in Major Inflammatory Rheumatic Diseases in Germany: a Nationwide Analysis of Hospital Discharge Data.

Rheumatology international·2026
Same author

[Acute diagnostics-focus on septic arthritis].

Zeitschrift fur Rheumatologie·2026
Same author

[School accidents revisited - A comparison oft wo five-year periods].

Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany))·2026
Same author

The Prevalence of Hospitalized Cases of Necrotizing Fasciitis: Anatomical Distribution, Amputations, and In-Hospital Mortality, 2019-2024.

Deutsches Arzteblatt international·2026

Related Experiment Video

Updated: Mar 19, 2026

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

3.1K

Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies.

Linxiao Chen1, Jenny L Valentine1, Chung-Jr Huang1

  • 1Robert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY 14853;

Proceedings of the National Academy of Sciences of the United States of America
|June 9, 2016
PubMed
Summary

This study introduces a novel method for creating glycoconjugate vaccines using engineered E. coli to produce glycosylated outer membrane vesicles (glycOMVs). These glycOMVs show promise as effective vaccines against bacterial pathogens like Francisella tularensis.

Keywords:
O-antigen polysaccharideanti-glycan antibodiesglycanglycoconjugate vaccinehumoral immune response

More Related Videos

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
08:09

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope

Published on: March 24, 2017

10.1K
Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

4.3K

Related Experiment Videos

Last Updated: Mar 19, 2026

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

3.1K
Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
08:09

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope

Published on: March 24, 2017

10.1K
Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

4.3K

Area of Science:

  • Microbiology
  • Vaccinology
  • Biotechnology

Background:

  • O-antigen polysaccharide (O-PS) is crucial for bacterial virulence and serves as a B-cell antigen.
  • O-PS glycoconjugate vaccines are effective but challenging to produce using traditional methods.
  • Current O-PS production methods are inefficient and costly.

Purpose of the Study:

  • To develop an alternative, efficient method for producing O-PS glycoconjugate vaccines.
  • To generate glycosylated outer membrane vesicles (glycOMVs) displaying pathogen-mimetic O-PS.
  • To evaluate the immunogenicity and protective efficacy of glycOMVs against Francisella tularensis.

Main Methods:

  • Coordinated recombinant O-PS biosynthesis with vesiculation in Escherichia coli.
  • Generated glycOMVs displaying O-PS from eight different pathogenic bacteria.
  • Utilized hypervesiculating E. coli to express F. tularensis O-PS gene clusters.

Main Results:

  • Successfully produced glycOMVs decorated with pathogen-mimetic glycotopes.
  • Immunization with glycOMVs elicited significant O-PS-specific IgG and IgA antibody titers.
  • GlycOMVs demonstrated significant protection against F. tularensis challenge in mice.

Conclusions:

  • GlycOMVs represent a promising platform for developing novel bacterial glycoconjugate vaccines.
  • The described method offers an accessible and adaptable approach for vaccine production.
  • This strategy could be extended to develop vaccines against a wide range of bacterial pathogens.